- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00567177
Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease
July 29, 2010 updated by: Innovative Medical
We propose to investigate the response to Restasis, over a prolonged period of time in heavy computer users with dry eye disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
6400 Fannin Ste 1800, Texas, United States, 77030
- Hermann Eye Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Using computers more than three hours per day
- Having dry eye symptoms based on results on the OSDI Scores of 15 or greater on the OSDI will be considered to have the disorder
- An abnormal confocal image of 5 or greater.
Exclusion Criteria:
- All corneal disorders except for tear disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: 2
|
Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
|
|
Active Comparator: 1
|
Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dry Eye disease
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
efficacy
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard Yee, MD, Hermann Eye Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Study Completion (Actual)
April 1, 2008
Study Registration Dates
First Submitted
November 30, 2007
First Submitted That Met QC Criteria
December 3, 2007
First Posted (Estimate)
December 4, 2007
Study Record Updates
Last Update Posted (Estimate)
July 30, 2010
Last Update Submitted That Met QC Criteria
July 29, 2010
Last Verified
July 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- HSC-MS-07-0421
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment of Dry Eye Disease
-
Jiangsu HengRui Medicine Co., Ltd.CompletedTreatment of Dry Eye Disease With Meibomian Gland DysfunctionChina
-
St. Joseph's Healthcare HamiltonNot yet recruitingGlaucoma | Dry Eye Disease (DED)
-
InMode MD Ltd.CompletedImprovement of Dry Eye DiseaseUnited States
-
The University of New South WalesUniversity of MelbourneRecruitingDry Eye Disease (DED)Australia
-
BioTissue Holdings, IncCompletedDry Eye | Dry Eye Disease (DED) | Dry Eye Disease With Severe KeratitisUnited States
-
Lawson Health Research InstituteUnknownDepression | Quality of Life | Eye Diseases | AnxietyCanada
-
Laboratoires TheaRecruitingDry Eye Disease (DED)Bulgaria
-
Dompé Farmaceutici S.p.ACompletedDry Eye DiseaseUnited States, Italy
-
Universiti Sains MalaysiaNot yet recruitingDry Eye Disease (DED) | Dry Eye Symptoms | Dry Eye Syndrome (DES)Malaysia
-
Singapore National Eye CentreThe Eye Hospital of Wenzhou Medical UniversityNot yet recruiting
Clinical Trials on Restasis, Refresh Plus
-
Julian M. Mackay-WigganAllerganCompleted
-
Seref istekUsak State HospitalCompleted
-
Korea Institute of Oriental MedicineDongGuk University; DONGSHIN University Oriental HospitalCompleted
-
Pro-Change Behavior SystemsNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
GlaxoSmithKlineCompletedMacular Degeneration | Age-related Macular DegenerationUnited States
-
Bispebjerg HospitalUniversity of Copenhagen; Arla FoodsCompleted
-
University of IowaCompletedEye Pain | Ocular Surface Disease | Cystoid Macular Edema | Central Retinal Vein Occlusion With Macular Edema | Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis) | Exudative Age-Related Macular Degeneration, Unspecified Eye | Dry Eye SensationUnited States
-
AbbVieRecruiting